We are all in
for better health

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business.

Discover more

Working together to help patients get the medicine they need

Our goal is to provide innovative treatments and quality generic and biosimilar medicines for millions of people

Learn more about our products

Stepping Up Innovation

Innovation for patients is at the heart of what we do, in every stage of drug development and delivery.

From in-house innovation to strategic partnerships, we are persistent in the creation of innovative medicines, generics and biologics to increase the accessibility and affordability of existing medicines.

Explore the Teva R&D pipeline

Careers at Teva

Four lab-coated professionals share ideas, emphasizing Teva's commitment to improving health daily.

Make a difference to people's health, every day

Working at Teva is not just a job, it’s so much more than that. Here, you get to spend each day helping millions of people around the world enjoy healthier lives. At the same time, you’ll be joining a dedicated team, united by the strong sense that we’re building something greater than ourselves

Explore a Teva Career

Take a closer look at what we do

Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug

Teva to Present at the Upcoming Investor Conferences in March

U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease

Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential

Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’

AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference